Nothing Special   »   [go: up one dir, main page]

Wöhrle et al., 2011 - Google Patents

FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF‐23 signaling and regulating FGF‐23 expression in bone

Wöhrle et al., 2011

View PDF @Full View
Document ID
6158028874934709336
Author
Wöhrle S
Bonny O
Beluch N
Gaulis S
Stamm C
Scheibler M
Müller M
Kinzel B
Thuery A
Brueggen J
Hynes N
Sellers W
Hofmann F
Graus‐Porta D
Publication year
Publication venue
Journal of Bone and Mineral Research

External Links

Snippet

The functional interaction between fibroblast growth factor 23 (FGF‐23) and Klotho in the control of vitamin D and phosphate homeostasis is manifested by the largely overlapping phenotypes of Fgf23‐and Klotho‐deficient mouse models. However, to date, targeted …
Continue reading at asbmr.onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00

Similar Documents

Publication Publication Date Title
Wöhrle et al. FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF‐23 signaling and regulating FGF‐23 expression in bone
Wöhrle et al. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23‐mediated hypophosphatemic rickets
Kang et al. Semaphorin 6D reverse signaling controls macrophage lipid metabolism and anti-inflammatory polarization
Agoro et al. Osteocytic FGF23 and its kidney function
Liu et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D
Bian et al. Klotho, stem cells, and aging
Li et al. Disruption of LRP6 in osteoblasts blunts the bone anabolic activity of PTH
Morvan et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass
Maes et al. VEGF‐independent cell‐autonomous functions of HIF‐1α regulating oxygen consumption in fetal cartilage are critical for chondrocyte survival
Nakamichi et al. VDR in osteoblast‐lineage cells primarily mediates vitamin D treatment‐induced increase in bone mass by suppressing bone resorption
Sotillo Rodriguez et al. Enhanced osteoclastogenesis causes osteopenia in twisted gastrulation‐deficient mice through increased BMP signaling
Samadfam et al. Bone formation regulates circulating concentrations of fibroblast growth factor 23
Yamazaki et al. Anti‐FGF23 neutralizing antibodies show the physiological role and structural features of FGF23
Martin et al. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling
Lee et al. A homozygous [Cys25] PTH (1‐84) mutation that impairs PTH/PTHrP receptor activation defines a novel form of hypoparathyroidism
Babu et al. Interaction between Dax-1 and steroidogenic factor-1 in vivo: increased adrenal responsiveness to ACTH in the absence of Dax-1
Ranch et al. Fibroblast growth factor 23 regulates renal 1, 25‐dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice
Duque et al. Pharmacological inhibition of PPARγ increases osteoblastogenesis and bone mass in male C57BL/6 mice
Bricceno et al. Histone deacetylase inhibition suppresses myogenin-dependent atrogene activation in spinal muscular atrophy mice
Lisse et al. The vitamin D receptor is required for activation of cWnt and hedgehog signaling in keratinocytes
Dardenne et al. Rescue of the pseudo‐vitamin D deficiency rickets phenotype of CYP27B1‐deficient mice by treatment with 1, 25‐dihydroxyvitamin D3: biochemical, histomorphometric, and biomechanical analyses
Louiset et al. The paradoxical increase in cortisol secretion induced by dexamethasone in primary pigmented nodular adrenocortical disease involves a glucocorticoid receptor-mediated effect of dexamethasone on protein kinase A catalytic subunits
Yuan et al. FGF‐23/Klotho signaling is not essential for the phosphaturic and anabolic functions of PTH
Yuan et al. Hexa‐D‐arginine treatment increases 7B2• PC2 activity in hyp‐mouse osteoblasts and rescues the HYP phenotype
Egan et al. Vitamin D receptor ligands, adenomatous polyposis coli, and the vitamin D receptor FokI polymorphism collectively modulate β‐catenin activity in colon cancer cells